FLC Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
FLC Capital Advisors's BMY Position: Q3 2026 in Review
FLC Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 10% in Q3 2026, selling an estimated $28.4K and leaving 3,891 shares worth $243K. The position accounts for 0.04% of the portfolio, ranked #195.
FLC Capital Advisors first reported a position in BMY in Q4 2018 and has held it in 26 quarters since. The position peaked at $487K in Q2 2022. 2,555 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- FLC Capital Advisors held 3,891 shares of Bristol-Myers Squibb worth $243K as of Q3 2026.
- FLC Capital Advisors sold 450 Bristol-Myers Squibb shares in Q3 2026, an estimated $28.4K.
- Bristol-Myers Squibb made up 0.04% of FLC Capital Advisors's portfolio in Q3 2026, its #195 holding.
- FLC Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 26 quarters since.
- FLC Capital Advisors's Bristol-Myers Squibb position peaked at $487K in Q2 2022.
- 2,555 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on FLC Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.